Protease-Activated Receptors: Contribution to Physiology and Disease
Top Cited Papers
Open Access
- 1 April 2004
- journal article
- review article
- Published by American Physiological Society in Physiological Reviews
- Vol. 84 (2) , 579-621
- https://doi.org/10.1152/physrev.00028.2003
Abstract
Ossovskaya, Valeria S., and Nigel W. Bunnett. Protease-Activated Receptors: Contribution to Physiology and Disease. Physiol Rev 84: 579–621, 2004; 10.1152/physrev.00028.2003.—Proteases acting at the surface of cells generate and destroy receptor agonists and activate and inactivate receptors, thereby making a vitally important contribution to signal transduction. Certain serine proteases that derive from the circulation (e.g., coagulation factors), inflammatory cells (e.g., mast cell and neutrophil proteases), and from multiple other sources (e.g., epithelial cells, neurons, bacteria, fungi) can cleave protease-activated receptors (PARs), a family of four G protein-coupled receptors. Cleavage within the extracellular amino terminus exposes a tethered ligand domain, which binds to and activates the receptors to initiate multiple signaling cascades. Despite this irreversible mechanism of activation, signaling by PARs is efficiently terminated by receptor desensitization (receptor phosphorylation and uncoupling from G proteins) and downregulation (receptor degradation by cell-surface and lysosomal proteases). Protease signaling in tissues depends on the generation and release of proteases, availability of cofactors, presence of protease inhibitors, and activation and inactivation of PARs. Many proteases that activate PARs are produced during tissue damage, and PARs make important contributions to tissue responses to injury, including hemostasis, repair, cell survival, inflammation, and pain. Drugs that mimic or interfere with these processes are attractive therapies: selective agonists of PARs may facilitatehealing, repair, and protection, whereas protease inhibitors and PAR antagonists can impede exacerbated inflammation and pain. Major future challenges will be to understand the role of proteases and PARs in physiological control mechanisms and human diseases and to develop selective agonists and antagonists that can be used to probe function and treat disease.Keywords
This publication has 299 references indexed in Scilit:
- Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotectiveNature Medicine, 2003
- Thrombin-stimulated Pyk2 phosphorylation in human endothelium is dependent on intracellular calcium and independent of protein kinase C and Src kinasesBiochemical and Biophysical Research Communications, 2002
- Dual effect mediated by protease‐activated receptors on the mechanical activity of rat colonBritish Journal of Pharmacology, 2002
- Trypsin is produced by and activates protease-activated receptor-2 in human cancer colon cells: Evidence for new autocrine loopLife Sciences, 2002
- Crystal structure reveals basis for the inhibitor resistance of human brain trypsinJournal of Molecular Biology, 2002
- In vivo functions of heterotrimeric G-proteins: studies in Gα-deficient miceOncogene, 2001
- Activation of Protease-Activated Receptor-2 (PAR-2) Triggers Mucin Secretion in the Rat Sublingual GlandBiochemical and Biophysical Research Communications, 2000
- Expression of protease-activated receptor-2 by osteoblastsBone, 2000
- Modulation of airway smooth muscle tone by protease activated receptor‐1,‐2,‐3 and ‐4 in trachea isolated from influenza A virus‐infected miceBritish Journal of Pharmacology, 2000
- Expression of Trypsin by Epithelial Cells of Various Tissues, Leukocytes, and Neurons in Human and MouseThe American Journal of Pathology, 1998